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E-mail address: anne.lespine@toulouse.inra.fr (A. LParasitic helminths cause signiﬁcant disease in animals and humans. In the absence of alternative treat-
ments, anthelmintics remain the principal agents for their control. Resistance extends to the most impor-
tant class of anthelmintics, the macrocyclic lactone endectocides (MLs), such as ivermectin, and presents
serious problems for the livestock industries and threatens to severely limit current parasite control
strategies in humans. Understanding drug resistance is important for optimizing and monitoring control,
and reducing further selection for resistance. Multidrug resistance (MDR) ABC transporters have been
implicated in ML resistance and contribute to resistance to a number of other anthelmintics. MDR trans-
porters, such as P-glycoproteins, are essential for many cellular processes that require the transport of
substrates across cell membranes. Being overexpressed in response to chemotherapy in tumour cells
and to ML-based treatment in nematodes, they lead to therapy failure by decreasing drug concentration
at the target. Several anthelmintics are inhibitors of these efﬂux pumps and appropriate combinations
can result in higher treatment efﬁcacy against parasites and reversal of resistance. However, this needs
to be balanced against possible increased toxicity to the host, or the components of the combination
selecting on the same genes involved in the resistance. Increased efﬁcacy could result from modifying
anthelmintic pharmacokinetics in the host or by blocking parasite transporters involved in resistance.
Combination of anthelmintics can be beneﬁcial for delaying selection for resistance. However, it should
be based on knowledge of resistance mechanisms and not simply on mode of action classes, and is best
started before resistance has been selected to any member of the combination. Increasing knowledge of
the MDR transporters involved in anthelmintic resistance in helminths will play an important role in
allowing for the identiﬁcation of markers to monitor the spread of resistance and to evaluate new tools
and management practices aimed at delaying its spread.
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Parasite helminths (nematodes, trematodes, cestodes, acantho-
cephala) are major causes of morbidity in animals and humans. In
livestock animals, these infections can lower growth rates and fer-
tility, decrease production of meat and milk, sometimes leading to
mortality of animals most infested and are of concern for animal
welfare. Helminths are also major pathogens of humans, infecting
more than one billion people worldwide (Hotez et al., 2008), and
causing many diseases such as hookworm disease, ascariasis,
whipworm disease, ﬁlariasis, onchocerciasis, schistosomiasis and
cysticercosis. Besides the huge suffering, they cause tens of thou-
sands of human deaths each year, reduce life expectancy and con-
demn millions to poverty (Hotez, 2009). With the rare exception of
a vaccine for Taenia infection in pigs, no vaccines are available for
these diseases and by far the major control measures in humans
and animals rely on the use of anthelmintic drugs.
Several classes of anthelmintics are currently available. Benzim-
idazoles (e.g., albendazole, fenbendazole, mebendazole, oxfendaz-
ole) and pro-benzimidazoles (e.g., febantel) have been used for
more than 50 years and owe their efﬁcacy to their selective ability
to bind to nematode tubulin (and that of some other invertebrates,
e.g., some protozoa, trematodes, cestodes and fungi) leading to
depolymerisation of microtubules and instability in the cytoskele-
ton of the target pathogens (Lubega and Prichard, 1990; McKellar
and Scott, 1990; Martin, 1997). Levamisole, pyrantel and morantel
are N-acetylcholine receptor agonists (Martin and Robertson,
2007), as is the new anthelmintic, monepantel, although the latter
appears to act on a different class of nicotinic receptors (Kaminsky
et al., 2008). Another new anthelmintic, derquantel, appears to be
an antagonist of the type of N-acetylcholine receptors upon which
levamisole acts (Qian et al., 2006). Emodepside appears to activate
NO and protein kinase C signalling pathways to produce slow acti-
vation of voltage-activated Ca-dependent SLO-1-like K channels
leading to paralysis of pharyngeal and body muscles in nematodes
(Buxton et al., 2011; Welz et al., 2011). Praziquantel is the principal
drug used for the control of schistosomiasis, some other trematode
infections and cestode infections. It appears to rapidly alter intra-
cellular calcium concentrations in ﬂatworms, leading to a rapid
paralysis. Triclabendazole is very effective against Fasciola spp.,
but inactive against schistosomes and cestodes. Its mode of action
is still not known. Today, the macrocyclic lactones (MLs) are the
most widely used anthelmintics in animal health and are impor-
tant in human health. MLs include ivermectin, abamectin, eprino-
mectin, doramectin and selamectin in the ML sub-class of
avermectins, and moxidectin and milbemycin oxime which are
both milbemycins. The MLs appear to primarily act onglutamate-gated chloride channels in nematodes (and some ecto-
parasites) (Cully et al., 1994) which are expressed widely in the
nervous system and on pharyngeal muscle (Wolstenholme and
Rogers, 2005). They bind allosterically to irreversibly open the
channel (Hibbs and Gouaux, 2011), leading to a permanent hyper-
polarisation of the cells and ﬂaccid paralysis. They may also have
effects on other ligand-gated chloride channels such as c-amino-
butyric acid (GABA) (Prichard, 2007) and dopamine-gated chloride
channels (Rao et al., 2009).
In veterinary medicine, the standards of anthelmintic efﬁciency
usually demand thatP95% of the parasitic nematodes be removed
with a single drug treatment and efﬁcacy below this, and certainly
below 90%, are accepted as evidence of anthelmintic resistance
provided that the anthelmintic has been administered at the
appropriate dose rate and other conditions, such as suitable formu-
lation, are satisﬁed (Coles et al., 2006). Currently used anthelmin-
tics, dose rates, formulations and treatment regimens very often
do not achieve the same high level of efﬁcacy against nematodes
in humans (Stepek et al., 2006; Keiser and Utzinger, 2008; Geary
et al., 2010) and as a result it may be much more difﬁcult to notice
an anthelmintic failure for which resistance could be suspected.
Current mass treatment campaigns against onchocerciasis, lym-
phatic ﬁlariasis (LF), schistosomiasis and soil transmitted hel-
minths (STH) are based on the use of drugs employed for
decades in the veterinary ﬁeld (Hotez et al., 2007). However, seri-
ous and often dramatic levels of anthelmintic resistance have been
recorded in veterinary parasites, mainly in ruminant and horse
gastro-intestinal nematodes (Kaplan, 2004; Demeler et al., 2009;
Gasbarre et al., 2009; El-Abdellati et al., 2011). There have been re-
ports of praziquantel resistance in Schistosoma mansoni (Fallon and
Doenhoff, 1994; Botros and Bennett, 2007), and more recently,
there is evidence of developing ivermectin (IVM) or macrocyclic
lactone (ML) resistance in Onchocerca volvulus (Osei-Atweneboana
et al., 2007, 2011) and Diroﬁlaria immitis (Blagburn et al., 2011;
Bourguinat et al., 2011a). Triclabendazole resistance, in Fasciola
hepatica has also been reported in many parts of the world
(Wolstenholme et al., 2004). Over the past 40 years, there have
been very few new classes of anthelmintic developed, and those
new classes, such as monepantel, derquantel and emodepside that
have been developed do not appear to have the breadth of spec-
trum, in terms of target hosts and parasite species, as the MLs
and benzimidazoles, and have not so far been developed for use
in humans. Furthermore, even with the introduction of new
anthelmintics, the risk of resistance developing relatively quickly
should not be under estimated and already it has been possible
to experimentally select for monepantel resistance in Haemonchus
contortus (Rufener et al., 2009).
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stand the mechanisms and genetics of anthelmintic resistance.
This understanding should be helpful in developing new anthel-
mintics, reducing the selection for resistance and maintaining the
efﬁcacy of anthelmintics, for monitoring the extent and spread of
anthelmintic resistance using sensitive and speciﬁc markers, to al-
low for anthelmintic combinations or synergists to be used which
will not share common mechanisms of resistance, and in some
cases for overcoming the resistance or exploiting the genetic
changes involved in resistance to speciﬁcally target drug resistant
parasites.
Drug resistance in pathogens results from the selection of a sub-
population of the pathogen which can tolerate the lethal or damag-
ing effects of the pharmaceutics which are normally or previously
effective against them. It is based on a selection of genes occurring
under drug pressure that will allow the target to survive. As it has a
genetic basis, it can be detected as changes in DNA sequences that
affect the functioning or expression of gene products.
To some extent, a too simplistic view of anthelmintic resistance
has been assumed, based solely on the mode of action receptor.
Commonly drug resistance involves more than a single genetic
change and very often non-receptor based mechanisms also con-
tribute to the resistance (Beech et al., 2011).
Targeted resistance is due to the mutation/alteration of the
receptor which is the target of the drug and is related to the mech-
anism of action of the drug. The latter can be due to (i) single
nucleotide polymorphisms (SNPs) or other genetic changes (e.g.,
indels) which alter the amino acid sequence of the drug receptor
(from single amino acid changes to premature stop codons or in-
tron deletions/insertions which effectively produce a null receptor)
and the afﬁnity of the receptor for the drug, (ii) changes in ancillary
proteins or other substances which affect the functioning of the
receptor, (iii) alteration in regulatory components which affect
the level of expression of a receptor or receptor ancillary protein,
(iv) changes in the importance of the receptor function to the via-
bility of the organism, or in (v) remediation or compensatory
mechanisms.
Benzimidazole resistance is mainly caused by speciﬁc amino
acid substitutions in b-tubulin due to the selection of SNPs at co-
don 200 (TTC to TAC; phenylalanine to tyrosine), codon 167 (TTC
to TAC) or codon 198 (GAA to GCA; glutamate to alanine) of b-
tubulin (Kwa et al., 1994, 1995; Silvestre and Cabaret, 2002; Ghisi
et al., 2007; Mottier and Prichard, 2008). Such polymorphisms in-
crease in frequency upon treatment and lead to treatment failure.
Resistance to levamisole is associated with genetic mutation on the
nAChR subunits involved in forming the levamisole receptor
(Boulin et al., 2011).
In the case of resistance to MLs, there is little evidence that ge-
netic changes to glutamate-gated chloride channels are signiﬁcant
for resistance in the ﬁeld (El-Abdellati et al., 2011; WilliamsonFig. 1. Multidrug transporter-mediated efﬂux of drug, its contribution to the developm
transporters on cell membranes of target organism: basal efﬂux of drugs (example with
pressure: increased efﬂux of drug and development of resistance. (C) Inhibition of MDR-
toxicity into the target cells.et al., 2011). The major mechanism of resistance to MLs in parasitic
nematodes, so far, implicates changes in multidrug ABC transport-
ers, as discussed below.
Surprisingly, other mechanisms such as overexpression of some
MDR transporters may modulate benzimidazole resistance
(Beugnet et al., 1997). In addition, there is evidence that macrocy-
clic lactones, such as ivermectin and moxidectin may select on
b-tubulin in nematodes such as H. contortus and O. volvulus (Eng
et al., 2006; Bourguinat et al., 2007) and in the case of H. contortus
the SNPs at codons 200 or 167 (TAC) associated with benzimid-
azole resistance may be selected (Mottier and Prichard, 2008;
Williamson et al., 2010). On the basis of these data, we can expect
that repeated use of ML anthelmintics may predispose nematodes
to benzimidazoles resistance. Interestingly, high afﬁnity binding of
the mammalian P-gp linker domain to a- and b-tubulin has been
reported (Georges, 2007), and this ﬁnding may provide further
insights into P-gp-interactions in the hosts and into drug resistance
in parasites.
These transporters are involved in non speciﬁc mechanisms
which can lead to cross-resistance by modulating the concentra-
tion of different drugs at their targets, compromising efﬁcacy.
The danger occasioned by this type of resistance is that several
classes of drugs having different modes of action may be concerned
and their efﬁciencies can be compromised at the same time.
2. Active transport of anthelmintics and its role in anthelmintic
resistance
Cross-resistance occurs through drug receptor-independent
mechanisms and arises because the mechanism of resistance to
several drugs is the same, through identical genetic mutations. In
any case, cross-resistance involving non speciﬁc mechanisms is ac-
quired through direct exposure to one drug and may generate
resistance to one or more other drugs to which the pathogen has
not been exposed. Non-receptor mechanisms of resistance include
altered levels of enzymes involved in drug metabolism or transport
mechanisms which modulate subsequently the concentration of
the drug that reaches the effector site on a receptor, such as (i) in-
creased efﬂux of the drug from cells containing the receptors, (ii)
reduced uptake, (iii) increased drug metabolism and inactivation
or (iv) reduced activation in the case of pro-drugs. Mechanisms
that alter drug concentration are sometimes referred to as non-
speciﬁc mechanisms because they may affect pharmaceuticals
from different chemical and mode of action classes. Some of the
most common mechanisms of drug resistance involve altered lev-
els or altered drug speciﬁcities of ABC (ATP binding cassette) trans-
porters, such as P-glycoprotein (Fig. 1).
ATP-binding-cassette transporters belong to an evolutionarily
well-conserved family of membrane proteins whose main function
is the ATP-dependent transport of a number of structurallyent of resistance and mechanism of reversion. (A) Constitutive expression of MDR
macrocyclic lactones). (B) Overexpression of MDR transporters in response to drug
mediated efﬂux with MDR reversal agents: enhancement of drug concentration and
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large range of drugs (Gottesman and Pastan, 1993). Among these
transporters, the multidrug resistance (MDR) ABC transport pro-
tein called P-glycoprotein (P-gp or MDR1 of the ABCB family)
was the ﬁrst active pump described for its overexpression in tu-
mour cells, leading to multidrug resistance (Dano, 1973). Besides
P-gp, the multidrug resistance proteins (MRPs of the ABCC family)
are also involved in multidrug resistance in mammals (Borst et al.,
1999), providing complementary and overlapping activities as
multispeciﬁc drug efﬂux pumps. The more recently discovered
member of the ‘half-transporter’ subfamily, Breast Cancer Resis-
tance Protein (BCRP) or ABCG2 (Doyle and Ross, 2003), gives a sim-
ilar drug resistance proﬁle, though not identical to P-gp containing
cells and is located alongside P-gp on barrier epithelia such as
intestine and the blood–brain-barrier. BCRP (Vlaming et al.,
2009) is also located in the placenta where it participates in the
protection of the foetus (Prouillac and Lecoeur, 2010), on stem cells
of various lineages (Krishnamurthy and Schuetz, 2006), and in
mammary glands during lactation, where it eliminates its sub-
strates in the milk (Jonker et al., 2005).
The complexity and also the performance of the system lies in
the ubiquitous presence of different transporters expressed at var-
ious levels and presenting considerable overlap in their substrate
speciﬁcities. By their action, these transporters provide an efﬁcient
barrier of protection for the organism from the toxicity of most
contaminants and they limit the entrance of many drugs, restrict-
ing their efﬁcacy. In addition, they play a clinically relevant role in
drug interactions when drugs are combined (Sarkadi et al., 2006).
Overall, they severely restrict the effectiveness of cytotoxic drugs,
designating them as major effectors of multidrug resistance in tu-
mour cells. Many ABC transporters are also found in nematodes,
protozoa, fungi and bacteria and some of them are involved in drug
resistance in these organisms. Indeed, drug resistance in pathogens
is very commonly associated with alterations in drug transport,
resulting in lower drug concentrations at the site of the relevant
drug receptor(s) than in susceptible strains.
2.1. Interaction of anthelmintic with mammalian MDR transporters
2.1.1. P-gp contributes to pharmaco- and toxico-kinetics of MLs
A considerable body of research has been carried out in order to
throw light on the role of P-gp on ivermectin pharmacology and
toxicology. Indeed, ivermectin was the ﬁrst ML designated as a P-
gp substrate when genetically engineered mice lacking the gene
coding for P-gp (mdr1a/) were treated with a standard antipar-
asitic procedure in the animal facility. The treated P-gp gene-mu-
tated mice showed signs of toxicity, and nearly all those
homozygous for the knock-out mutation died; they were found
to have a 100-fold higher ivermectin concentration in their brain
than the wild type mice (Schinkel et al., 1994). This is consistent
with the property of MLs to bind to GABA receptors in the central
nervous systems of mammals. In the same vein, ivermectin hyper-
sensitivity with neurotoxicity was observed in a subpopulation of
CF1 mice (Kwei et al., 1999) and in Collie dogs (Mealey et al.,
2001; Roulet et al., 2003) where it was also associated with a
mutation in the P-gp gene. P-gp is thus clearly responsible for pre-
venting ivermectin from entering the brain tissue, and its role is
extended to controlling the tissue distribution of the drug in the
whole organism (Schinkel et al., 1994).
P-gp is also located on the apical surface of the enterocytes and
hepatocytes, and thus expels drugs into the intestinal lumen and
the bile. A strong accumulation of ivermectin (10-fold) occurred
in the gall bladder cells in P-gp deﬁcient mice (Schinkel et al.,
1994) and biliary secretion was originally thought to be the major
route of ML excretion (Hennessy and Alvinerie, 2002). Neverthe-
less, P-gp mediated intestinal secretion plays a greater role thanbiliary secretion in the overall elimination of ivermectin in the
rat (Laffont et al., 2002; Ballent et al., 2006; Kiki-Mvouaka et al.,
2010). These results support the extensive elimination of MLs by
the faecal route and the main consequence of P-gp action is to limit
the systemic level of ivermectin and the duration of animal drug
exposure and subsequently limit drug efﬁcacy.
More than 50 ABCB1 single nucleotide polymorphisms (SNPs)
have been identiﬁed in humans and several have been associated
with low P-gp function (Fung and Gottesman, 2009). Much interest
has been focused on the frequently found polymorphism at posi-
tion 3435 in the middle of exon 26, which changes cytosine to thy-
mine. It is a synonymous mutation that translates to isoleucine, a
hydrophobic amino acid residue found in the second ATP-binding
domain. In general, the 3435C alleles are more frequent than T al-
leles hence considered as wild-type and individuals with 3435T
polymorphism had signiﬁcantly lower duodenal P-gp expression
and activity (Hoffmeyer et al., 2000). P-gp gene deletion associated
with a complete lack of P-gp function has previously been de-
scribed in several canine breeds (Mealey et al., 2001; Roulet
et al., 2003), while in humans, there is no genotype described so
far associated with a full lack of P-gp function. However, the im-
pact of P-gp gene polymorphisms on the pharmacokinetics and
pharmacodynamics of P-gp substrates in clinical conditions is still
under debate.
Ivermectin has been used for more than 20 years in humans
mainly in African populations for mass treatment (several hundred
million people have been treated) to treat onchocerciasis and lym-
phatic ﬁlariasis (Molyneux et al., 2003) and it appears exception-
ally safe. However, it is possible that signs of neurotoxicity have
been underestimated or misinterpreted. A small number of cases
of encephalopathy, sometimes fatal, have been reported in some
individuals who harboured large numbers of Loa loa microﬁlariae.
In a recent study, the question was raised whether the treatment of
individuals with high Loa burdens with ivermectin combined with
a P-gp polymorphism could be responsible for these effects. This
hypothesis was tested in four individuals from Cameroon who
experienced a post-ivermectin serious adverse event and in nine
matched controls. No loss-of-function mutation was detected in
P-gp in any subject. However, haplotypes associated with altered
drug disposition, were present as homozygote in two of the pa-
tients presenting post-ivermectin adverse effect (50%), but absent
as homozygotes in the controls (0%). Although the number of sub-
jects was very low, these data suggest that an association of high
Loa microﬁlarial load with a genetic predisposition to altered iver-
mectin distribution could be involved in ivermectin adverse events
(Bourguinat et al., 2010).
The synonymous polymorphism 3435C allele associated with
the highest expression levels of P-gp (Hoffmeyer et al., 2000) has
been frequently found in African populations (Ameyaw et al.,
2001) and may contribute to the lack of ivermectin neurotoxicity
in this population. This does not predict the safety of ivermectin
in other populations, in particular in Caucasian and Asian popula-
tions for which the more frequent ABCB1 polymorphism is 3435T,
which is associated with low P-gp expression. This may imply
additional caution in the use of ivermectin in human clinics. This
is even more complex as haplotypes provide different possible alle-
lic combinations.
Given that nematodes have P-gps located in their intestine
(Zhao et al., 2004), it is hypothesized that similar efﬂux functions
occur in parasites and limit drug entrance and efﬁcacy, but no di-
rect evidence of ML transport by nematodes P-gps has been pro-
vided so far.
2.1.2. MLs are strong inhibitors of P-gp transport activity
For some time ivermectin has been known to be a member of
the impressive list of inhibitors of P-gp-mediated transport (Didier
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activity. Because MLs are slowly transported by P-gp, it is sug-
gested that when ivermectin binds to P-gp, the binding sites be-
come unavailable to other compounds. The strong potency of
ivermectin to inhibit P-gp is in the same range as the most effective
P-gp ligands reported to date, such as cyclosporin A, its derivative
PSC833 (Valspodar), or the antidiarrheal opioid drug loperamide
(Eneroth et al., 2001) which are much more potent than verapamil
that has long been used as the reference inhibitor for P-gp trans-
port. Different inhibitory capacities have been reported for differ-
ent MLs on the basis of two different approaches: (i) the ability
of P-gp to transport the reference ﬂuorescent substrate rhodamine
123, and (ii) the ATPase activity of the transporter which can be
modulated by inhibitors. Moxidectin was found to be a poor inhib-
itor when compared to ivermectin, selamectin, eprinomectin, aba-
mectin or doramectin. This could be due to the structural
speciﬁcity of milbemycins which lack, for example, the
di(mono)saccharide moiety when compared to avermectins
(Lespine et al., 2007), and related to the poor ability of P-gp to
transport moxidectin in vitro and in vivo when compared to aver-
mectins. Indeed, plasma kinetics of moxidectin are not inﬂuenced
by the lack of P-gp in mice and moxidectin is mostly excreted via
a P-gp-independent pathway at the intestinal barrier (Kiki-Mvoua-
ka et al., 2010) and it is not actively transported by P-gp in Caco2
cells (Grifﬁn et al., 2005). By contrast, ivermectin is clearly
transported in the two systems. However, moxidectin was clearly
efﬂuxed by P-gp at the blood–brain barrier (Kiki-Mvouaka et al.,
2010). These results suggest tissue speciﬁcity in the efﬂux mecha-
nisms at the transporter level and differences between molecules
of the same family in terms of their ability to interact with mam-
malian P-gp, which may also occur with parasite P-gps.
2.1.3. MLs interact with other mammalian MDR transporters
Until recently, the focus of attention has been the interaction of
MLs with P-gp. However, there is now information describing the
interaction of MLs with several other MDR transporters. Ivermectin
interacts with MRP1, and to a lesser extend with MRP2 and MRP3
(Lespine et al., 2006). However, interaction of ivermectin with
MRPs is weak comparing with its interaction with P-gp. Data
showing the lower accumulation of ivermectin in cells over-
expressing MDR1 together with the polycyclic structure and lipo-
philic nature of ivermectin strongly suggest that ivermectin
could also be a MRP transport substrate, even though this has been
controversial (Brayden and Grifﬁn, 2008).
Ivermectin also efﬁciently inhibits human BCRP (Muenster
et al., 2008; Jani et al., 2010) and sheep BCRP (Real et al., 2011).
No data are available on the direct transport of ivermectin by BCRP.
Nevertheless, moxidectin was identiﬁed as a BCRP substrate since
its Bcrp1-mediated secretion into breast milk and the involvement
of Bcrp1 in intestinal and bile secretion has been demonstrated in
mice (Perez et al., 2009). Given the role of BCRP in efﬂuxing sub-
strates into the milk (Jonker et al., 2005), these interactions with
BCRP have pharmacokinetic and toxicological consequences,
mainly with respect to the presence of drug residues in milk fol-
lowing ivermectin or moxidectin treatment.
It would also be of interest to investigate its role in the differen-
tial elimination of MLs in the milk of treated animals. Indeed, the
low elimination of eprinomectin in milk compared with other
MLs could be due to a lower transport of this drug by BCRP. This
point remains to be investigated. Because the afﬁnities of ivermec-
tin for MRPs and BCRP in mammals are weaker than for P-gp, the
role of the non-P-gp transporters may be limited due to the mask-
ing effect of P-gp. MRP1 is detected in the brain (Rao et al., 1999;
Nies et al., 2004), but its function appears to be limited or contro-
versial (Borst et al., 1999). Indeed, the marked ivermectin neuro-
toxicity in animals lacking P-gp reveals that MRP1 or other MRPsdo not compensate for the absence of P-gp in the blood–brain
barrier. Similarly, BCRP is also expressed at the blood–brain barrier
(Cooray et al., 2002) and it is overexpressed in P-gp-deﬁcient mice
(Cisternino et al., 2004), but it does not protect the brain against
ivermectin toxicity. Thus, P-gp clearly remains the main actor for
ivermectin efﬂux out of brain. Nevertheless, the individual speciﬁc
contribution of each transporter remains to be deﬁned more pre-
cisely. If it is conﬁrmed that ivermectin is transported by MRPs
or BCRP, cooperation may exist between the various MDR trans-
porters whose functions are determined by both their expression
levels in tissues and their afﬁnities for the substrate drugs. This
complexity of the mechanisms that transport compounds out of
the organism means that different complementary approaches,
including integrated in vivo assays, will be necessary to deﬁne
the precise and the respective roles of P-gp, MRPs and BCRP in
ML pharmaco- and toxicokinetics and dictates focusing on the con-
tribution of several transporters in investigating ivermectin resis-
tance rather than a single transporter.
2.1.4. Other anthelmintics interact with MDR transporters
Benzimidazoles have been claimed to interact speciﬁcally with
P-gp and have been shown to be substrates for P-glycoprotein
mediated drug efﬂux (Nare et al., 1994). This is in full agreement
with the fact that benzimidazole pharmacokinetics is inﬂuenced
by MDR transporters in vivo (Jonker et al., 2000). Indeed, triclaben-
dazole and triclabendazole sulfoxide inhibit the transport activity
of P-gp and these benzimidazoles were less toxic in cells over-
expressing P-gp, which suggests that they are efﬂuxed by P-gp.
However, triclabendazole sulphone, albendazole, mebendazole,
oxfendazole and thiabendazole failed to have any effect on P-gp
activity (Dupuy et al., 2010). Nevertheless, albendazole sulfoxide
and oxfendazole (the sulfoxide of fenbendazole) have been shown
to be transported in vitro by BCRP, whereas albendazole and fen-
bendazole were neither transported by nor inhibited the pump
(Merino et al., 2005). The use of efﬁcacious BCRP or P-gp inhibitors
might increase the extent and duration of systemic exposure to
albendazole sulfoxide and oxfendazole, with possible beneﬁcial
therapeutically effects in extra-intestinal infections.
In cells overexpressing mammalian P-gp, closantel and rafoxa-
nide were shown to interact strongly with and are transported
by P-gp, while nitroxynil, levamisole, praziquantel and clorsulon
failed to have any effect on P-gp activity (Dupuy et al., 2010). These
data need to be completed by studying the interaction of these
drugs with other MDR transporter and interactions may occur
through other transporters or metabolizing enzymes. This informa-
tion is of major interest for predicting P-gp–drug interactions
when formulations combining several anthelmintics are adminis-
tered, or when two anthelmintics are administered at the same
time, and is crucial for the optimization of anthelmintic efﬁcacy.
It should be noted that the effects of recently marketed anthelmin-
tics such as monepantel and derivatives, derquantel on MDR trans-
porters remains to be elucidated.
2.1.5. MLs as reversal agents for multidrug resistance in cancer cells
Effective anticancer treatment usually requires the use of multi-
ple cytotoxic drugs, since resistance to single agents occurs almost
universally. Nevertheless, a common mechanism that confers
simultaneous resistance to different drugs, based on drug efﬂux
from cancer cells mediated by MDR transporters, represents a crit-
ical phenomenon hampering anticancer chemotherapy (Fig. 1). As
a result, it is highly desirable to overcome this type of resistance
(Szakacs et al., 2006). Despite the clear rationale for the use of
inhibitors of MDR transporters, especially of P-gp, to sensitize
drug-resistant cell lines to known drug substrates, the develop-
ment and exploitation of these inhibitors has been slow. The bot-
tlenecks are the unwelcome inhibition of MDR transporters at
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the compounds used, so far, as reversing agents. Some promising
MDR reversing agents, including valspodar or verapamil deriva-
tives, had been under clinical trial but have been abandoned be-
cause of intolerable side effects (Sarkadi et al., 2006). The afﬁnity
of MLs for P-gp is among the highest described to date (Lespine
et al., 2007). It is probable that their large molecular sizes results
in their afﬁnity to several binding sub-sites on P-gp overlaps. As
a consequence, they should compete with a large number of P-gp
substrates. In addition, they also inhibit MRP1 and BCRP which
makes their action not restricted to P-gp and, at least theoretically,
makes it possible to design an efﬁcient MDR reversal agent what-
ever the relevant MDR transporter involved.
The high efﬁciency of MDR reversal by avermectins was demon-
strated in cultured tumour cells overexpressing P-gp (Pouliot et al.,
1997; Korystov et al., 2004). Ivermectin was able to increase vin-
balstine efﬁcacy in vinblastine-resistant human lymphoma cells
(Pouliot et al., 1997). In vincristine-resistant human lympholeuke-
mic cells P388 and in taxol-resistant larynx tumour Hep-2 cells,
ivermectin was more effective than the traditional MDR transport
inhibitor cyclosporine A (Korystov et al., 2004). The milbemycin
compounds were recently shown to be also potent MDR reversing
agent in adriamycin-resistant cancer cells overexpressing P-gp
(Gao et al., 2011). In these cells, the avermectin, doramectin, was
more potent in reversing MDR than the milbemycin, nemadectin,
original compound used for moxidectin production (Gao et al.,
2010). A relationship between structure and the function in terms
of the interaction of MLs with P-gp has been clearly established
(Lespine et al., 2007), and may impact on the potency of MLs of dif-
ferent structure to reverse MDR.
Owing to the strong interaction of avermectins with the MDR
transporters, they have been proposed as possible reversal agentsTable 1
Inﬂuence of MDR modulators on the disposition and anthelmintic efﬁcacy of MLs in vivo.




AUC (fold increase)f Nematode
species
Ketoconazole SC IVM Dog 2 nd
Oral IVM Sheep 1.8 nd
Ketoconazole Oral IVM Sheep 1.9 H. contortus
Pluronic 85 Oral IVM Sheep 1.9 H. contortus
Itraconazole IR IVM Sheep 3.8 nd
SC IVM Rat 2 nd
Verapamil IVM Jird Nd H. contortus
PO IVM Rat 1.4 nd
Oral IVM Sheep 1.6 nd
Oral MOX Sheep –1.5 nd
Valspodar SC IVM Rat 2 nd
Quercetine SC MOX Sheep 1.8 nd
Loperamide SC IVM Rat 1.8 nd
SC MOX Cattle 1.5 nd
SC IVM Sheep 1.5 H. contortus
T. colubriformis
SC MOX Cattle 1.3 Cooperia spp. and
SC IVM Cattle 1.3 Cooperia spp. and
Triclabendazole IV IVM Sheep 3.4 nd
Oral MOX Sheep nd T. circumcincta, Tr
Nematodirus spp.,
Albendazole SC IVM Sheep 1.9 nc
Closantel IVM Cattle 1.0 nd
Rafoxanide SC IVM Calves 1.15a nd
SC IVM Sheep 1.15 nd
Spinosad Oral IVM Dog 3.6 nd
Danoﬂoxacin IVM Sheep 1.0b nd
Levamizole Oral IVM Humans 2.0 nd
Azithromycin Oral IVM Humans 1.3 nd
SC: subcutaneous; IR: intraruminal; PO: pour on; IVM: ivermectin; MOX: moxidectin; n
a Rate of elimination increased by 30%.
b Excretion in milk increased by 40%.
c Cooperia spp. was the most abundant nematode recovered after the different drug tto potentiate chemotherapy based on MDR transporter substrates.
However, such a possibility was rapidly rejected because of the po-
tential neurotoxicity of MLs which dictates caution for their use in
humans, in particular when co-administered with another MDR
substrate and potential MDR inhibitor in clinical situations. In this
respect, it would also be of major interest to know the ability of dif-
ferent MLs to bind to mammalian GABA receptors implicated in
their mammalian neurotoxicity. The challenge then, in order to de-
velop an optimal strategy for MDR reversal, is to screen and select
among the large number of ML derivatives available, or to design
new derivatives, that will combine high afﬁnity for P-gp with
low toxicity.
2.1.6. Anthelmintic-drug interaction through modulations of MDR
transporter activity
A large number of compounds such as drugs, and other natural
or synthetic substances, other than avermectins, have been shown
to inhibit MDR transporters. In a situation when MLs and those
inhibitors are present at the same time in the same organism, we
can expect that the respective disposition of the ML and/or of the
inhibitor will be modiﬁed.
A number of veterinary drugs known to interact with MDR
transporters have been co-administered to animalswith ivermectin
(Table 1). The fungicide ketoconazole increased ivermectin exposi-
tion (AUC) by 2-fold in sheep and in dogs (Hugnet et al., 2007;
Alvinerie et al., 2008). Loperamide, an opioid derivative that has
been classiﬁed as a P-gp substrate (Schinkel et al., 1996; Sartor
et al., 2004), also increased ivermectin or moxidectin availability
in several animal species (Lifschitz et al., 2002, 2004, 2010a,b).
Neurological side effects consistentwithMLs toxicity have been ob-
served in dogs when high doses of milbemycin 5-oxime, used as a
heartworm prevention agent, were co-administered with spinosad,Improvment of efﬁcacy References
nd Hugnet et al. (2007)
nd Alvinerie et al. (2008)
nc
+ Bartley, personal communication
nd Ballent et al. (2007)
nd Ballent et al. (2006)
+ Xu et al. (1998)
nd Alvinerie et al. (1999)
nd Molento et al. (2004)
nd Molento et al. (2004)
nd Ballent et al. (2006)
nd Dupuy et al. (2003)
nd Lifschitz et al. (2004)
nd Lifschitz et al. (2002)
0–72.5% Lifschitz et al. (2010a)
77.9–93.3% Lifschitz et al. (2010a)
Ostertagia spp. 23.0–50.0%c Lifschitz et al. (2010b)
Ostertagia spp. 69.0–87.0%c Lifschitz et al. (2010b)
nd Lifschitz et al. (2009)
ichostrongylus spp.,
Trichuris
Efﬁcacy of 95% Martinez-Valladares et al. (2010)
nc Alvarez et al. (2008)
nd Cr omie et al. (2006)
nd El-banna et al. (2008)
nd
nd Dunn et al. (2011)
nd Real et al. (2011)
nd Awadzi et al. (2004b)
nd Amsden et al. (2007)
d: not determined; nc: no change; +: increased efﬁcacy.
reatments.
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sad is a strong inhibitor of P-gp and its co-administration with iver-
mectin led to a 3.6-fold increase in the AUC of ivermectin when
compared with the control administered ivermectin alone (Dunn
et al., 2011). Ivermectin, co-administered in sheep with ﬂuoroquin-
olone danoﬂoxacin, a BCRP substrate, had no signiﬁcant effect on
the plasma levels of danoﬂoxacin but signiﬁcantly decreased dano-
ﬂoxacin concentrations in milk by almost 40% (Real et al., 2011).
This is consistent with the potency of ivermectin to inhibit BCRP
(Jani et al., 2010). Given the presence of BCRP in the mammary
gland and because of potential drug–drug interactions mediated
by BCRP, concomitant administration of multiple drugs, often used
in veterinary or human therapy, may not only affect their pharma-
cological activity but also their secretion into milk.
Similarly, anthelmintics are sometimes combined with iver-
mectin in livestock to broaden the antiparasitic activity spectrum.
Triclabendazole associated with ivermectin or moxidectin affects
the ML kinetics in sheep (Lifschitz et al., 2009). The combination
of closantel and ivermectin in cattle led to a more rapid ivermectin
absorption and excretion and a higher maximal concentration
(Cmax), although the AUC of both formulations were not signiﬁ-
cantly different (Cromie et al., 2006). In addition, the disposition
kinetics of ivermectin were changed when administered in combi-
nation with rafoxanide with increase of ivermectin AUC by 15%,
and decrease in the rate of elimination by 30% (El-Banna et al.,
2008). Albendazole sulfoxide when co-administered to sheep with
the antibacterial agent, and BCRP substrate, enroﬂoxacine decrease
the secretion of the latter drug into milk, in agreement with the
presence of BCRP in the mammary gland and with the inhibitor po-
tential of albendazole sulfoxide on BCRP (Pulido et al., 2006). This
is in agreement with the capacity of triclabendazole, triclabendaz-
ole sulfoxide, closantel and rafoxanide to interact in vitrowith P-gp
(Dupuy et al., 2010) and of albendazole sulfoxide and oxfendazole
with BCRP (Merino et al., 2005).
Some of these anthelminthic drugs are also used at the same
time or can be combined with other P-gp-substrate drugs in hu-
mans. This can be the case of ivermectin or albendazole with lop-
eramide (antidiarrheal agent), doxorubicin, vincristine, vinblastine
(anticancer agents), cyclosporin A (immunosuppressive agent),
antiviral drugs (acquired immunodeﬁciency syndrome treat-
ments), digoxin (antiarrhythmic agent), acepromazine (tranquil-
izer), butorphanol (opioid analgesic) and quinine (antimalarial
drug). Thus, such association might induce interactions and should
be considered with caution when administered in patients.
As an example, interactions of levamizole with ivermectin or
with albendazole were reported in 42 healthy male volunteers. A
signiﬁcant increase in the bioavailability of ivermectin and a
signiﬁcant reduction in that of albendazole sulfoxide (following
albendazole administration) were observed when these drugs
were co-administered with levamisole (Awadzi et al., 2004b).
Azithromycin, the sole member of the 15-membered macrolide
structured sub-class known as azalides, has currently become the
standard for mass treatment of villages in trachoma-endemic
areas. Azithromycin has been shown to be a substrate of P-gp (Ser-
al et al., 2003). Because azithromycin is likely to be associated with
ivermectin treatment in countries where bacterial infections and
onchocerciasis or lymphatic ﬁlariasis are prevalent, several drug–
drug interaction studies have been conducted in humans combin-
ing ivermectin with azithromycin administration. A 31% increase
in ivermectin AUC was observed when ivermectin was co-adminis-
tered with azithromycin (Amsden et al., 2007).
Other anthelmintic drug interactions were reported for the
pharmacokinetics of praziquantel and albendazole. In healthy
volunteers the co-administration resulted in an increased plasma
concentration of albendazolemetabolites and of praziquantel (Lima
et al., 2011). Clinically, the combination of these two drugs mayimprove the therapeutic efﬁcacy as a consequence of higher concen-
tration of both active drugs. Praziquantel or albendazole do not
interact in vitro with P-gp or BCRP (Merino et al., 2005; Dupuy
et al., 2010) but albendazole sulfoxide, the major metabolite of
albendazole, is a BCRP substrate (Jonker et al., 2005). Because these
drugs are highlymetabolized by biotransformation enzymes (Virkel
et al., 2004) we cannot exclude the possibility that they interact
through modulation of cytochrome P450 or ﬂavin monoxygenase.
Before envisaging combination, it is crucial to evaluate the
interactions of drugs including effects on MDR transporters.
2.1.7. Modulation of MDR gene expression in mammals: possible
inﬂuence of MLs
Another possible interaction between MLs and MDR transport-
ers concerns the ability of the drug to modulate the expression of
transporter genes. Indeed, it is recognized that, among many fac-
tors and cellular signalling pathways that play a role in the regula-
tion of MDR gene expression, drug exposure and the ability of
drugs to interact with MDR transporters can lead to overexpression
of these proteins (Schrenk et al., 2001). Furthermore, considerable
evidence has accumulated to indicate that the expression of drug
transporter genes can be rapidly and transiently induced following
treatment by chemotherapeutic agents (Chin et al., 1990). The sub-
sequent change in the activity of the transporter can have a major
impact on metabolism, toxicity and drug–drug interactions of
many xenobiotics or endogenous substances and can also impact
on the efﬁcacy of drugs. Indeed, even a moderate increase of P-
gp expression was shown to be associated with resistance to the
anticancer drug doxorubicin (Pajic et al., 2009).
In mammals, the regulation of the detoxiﬁcation network oc-
curs mainly by transcriptional events through activation of speciﬁc
nuclear receptors, termed ‘‘xenosensors’’, belonging to the family
of ligand-activated transcription factors (Klaassen and Slitt,
2005). Numerous nuclear receptor proteins have been shown to
be involved in transcription of drug transporters such as the reti-
noic acid receptor (RAR), farnesoid receptor (FXR), liver X receptor
(LXR) and peroxisome proliferator-activated receptors a and c
(PPARa and PPARc) (Zhou, 2008). Pregnane X receptor (PXR) and
constitutive androstane receptor (CAR), two other xenosensors,
are now both widely recognized to play the most important role
in the regulation of MDR1 (Wei et al., 2000; Synold et al., 2001;
Maglich et al., 2003). Apart from transcriptional regulation, overex-
pression of P-glycoprotein has also been shown to be controlled
partially through post-transcriptional mechanisms, such as mRNA
stabilization (Lee et al., 1995; Lee et al., 1998) or modulation of the
translational initiation (Yague et al., 2003; Gomez-Martinez et al.,
2007). In addition to altering the expression or activity of transact-
ing factors, the transcriptional output of genes can also be affected
by more dramatic and permanent genomic alterations, such as
translocations, mutations or gene ampliﬁcation. Indeed, in numer-
ous cancer cells, resistance to chemotherapeutic agents has been
attributed to an increase of copy number of the MDR1 transporter
gene leading to an increase in the transporter protein expression
(Hattinger et al., 2009). Moreover, MDR1 promoter mutations that
may alter transcription have also been identiﬁed (Stein et al.,
1994). Finally, some recent, exciting results have shown that epige-
netic events, such as DNA methylation (Reed et al., 2010) or his-
tone acetylation (Jin and Scotto, 1998; Baker et al., 2005; Huo
et al., 2010), also control expression and function of MDR trans-
porters in response to multiple inducers and that these effects
can be correlated with the acquisition of drug resistance in mam-
malian tumour cells. Thus, it is likely that multiple mechanisms ex-
ist in different cell types that either cooperatively or exclusively
regulate MDR1 gene output.
Since ivermectin is a substrate of P-gp and other efﬂux trans-
porters, it may be able to regulate the expression level of these pro-
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(Schrenk et al., 2001). In mammalian cells ivermectin was shown
to induce the expression of the mdr1 gene encoding for P-gp
through post-transcriptional mRNA stabilization, thus offering in-
sight into the mechanism of reduced therapeutic efﬁcacy and
development of ivermectin-resistance (Ménez et al., 2011). In addi-
tion, a 24 h exposure of cancer cells to MLs (doramectin or nema-
mectin) was able to reverse the resistance to anticancer drug not
only through inhibition of the transporter activity but also through
a decrease in the expression of the P-gp gene (Gao et al., 2010).
Modulation of MDR transporter function and expression may
represent a useful approach in the management of drug resistance.
A better understanding of different mechanism of regulation of the
expression of the MDR transporters can help in proposing strate-
gies to improve efﬁcacy, minimizing drug toxicity and unfavour-
able drug–drug interactions, and to overcome drug resistance.
2.2. Genetic diversity and abundance of MDR transporters in helminths
In contrast to the situation in mammals which have a few MDR
transporters, nematodes have a number of genes homologous to
ABCB1 (coding for P-gps), ABCCs (coding for MRPs), and half trans-
porters which, in nematodes, are more closely related to the ABCB
sub-family, than the ABCG2 sub-family, such as BCRP, which can be
involved in xenobiotic transport in mammals. The reason for this
diversity in nematodes is unknown, but it was recently suggested
that they might be essential to protect different neurons in the
body of the nematodes from a broad spectrum of toxins (Prichard
and Roulet, 2007). Sixty ABC transporter genes have been identi-
ﬁed in the Caenorhabditis elegans genome (Sheps et al., 2004). How-
ever, many of these are likely to be involved with the speciﬁc
transport of endogenous metabolites. Of those that may possibly
be involved in the efﬂux of xenobiotics, 14 P-gp encoding genes
and a P-gp pseudogene, eight multidrug resistance protein (MRP)
and nine Haf (half-transporters) genes have been identiﬁed in
the genome of C. elegans. The precise role of these genes in C. ele-
gans development and behaviour needs further investigation.
However, not all of the C. elegans ABC transporters are expressed
in all developmental stages, and in the adult worms, ABC transport
proteins are expressed in excretory cells, the intestine, amphids,
neurons, hypodermis, muscle, pharynx and spermatheca in her-
maphrodites and males, as well as in the vulva in hermaphrodites,
and the male tail (Zhao et al., 2004). In C. elegans, P-gp1 and P-gp3
have been explored for their role in detoxiﬁcation. P-gp3 deletion
mutants became sensitive to colchicine and chloroquine but not
those with P-gp1 deleted (Broeks et al., 1995). Similarly, targeted
inactivation of mrp-l resulted in increased sensitivity to the heavy
metal ions cadmium and arsenite, to which wild-type worms are
highly tolerant. Nematodes were found to be hypersensitive to
heavy metals when both mrp-1 and P-gp-1 were deleted (Broeks
et al., 1996). These data indicate that different P-gps or MRPs par-
ticipate in protecting the worms, depending on the toxin, and that
several transporters may acts in combination to ensure optimal
protection.
Ardelli et al. have analyzed the Brugia malayi genome and con-
cluded that there are probably eight P-gps, eight half-transporters
(also of the ABCB sub-family in nematodes) and ﬁve MRP (ABCC)
genes (Ardelli et al., 2010). In H. contortus, full or partial sequences
of nine P-gps (Williamson and Wolstenholme, 2011), one haf and
twomrp genes have been described. However, preliminary analysis
of the partial H. contortus genome indicates that more ABC trans-
porter genes may be present. In O. volvulus, four P-gp and three
half-transporters are reported (Huang and Prichard, 1999; Ardelli
and Prichard, 2004, 2007; Ardelli et al., 2005, 2006a,b; Bourguinat
et al., 2008). In cyathostomins at least two P-gp genes have been
described (Drogemuller et al., 2004). Although the number of P-gp genes so far identiﬁed in nematode parasites appears smaller
than in the free living nematode C. elegans, this is probably in part
because the genomes of most parasitic nematodes have yet to be
completed and annotated. More research is necessary on these
gene families to number exhaustively the transporter genes pres-
ent in parasitic nematode species, to determine where they are ex-
pressed and to decipher what role they play in the efﬂux of
anthelmintics drugs and other substances. There is evidence that
H. contortus P-gp-A (a probable homologue of C. elegans P-gp2) is
expressed in the posterior pharynx and the anterior intestine
(Smith and Prichard, 2002). GFP-transgene expression in C. elegans
indicates that Cel-P-gp2 is expressed in the pharynx of this free-liv-
ing nematode (Zhao et al., 2004). Antibody staining indicates that
P-gp is present in the shell of eggs, and cuticle of adult and larval
stages of H. contortus (Riou et al., 2005). In the chitinous shell of
nematode eggs, the P-gp is localized in lipid microdomains that
correspond to the raft-like structures containing proteins found
in plasma membrane. The nematode egg shell and cuticle P-gp
may play a role in efﬂuxing xenobiotics from the eggs and vermi-
form stages (Riou et al., 2010).
2.3. Interaction of anthelmintics with parasite MDR transporters
Almost all studies have been performed with mammalian trans-
porters and given that several P-gps are also expressed in the nem-
atode intestine (Zhao et al., 2004), it is likely that they play a
similar role in modulating ML uptake to, and excretion from para-
sitic nematode tissues, possibly modulating ML concentrations at
receptor sites in nerve or muscle membranes. Studies which indi-
cate a role for ABC transporters in anthelmintic resistance in hel-
minth species are summarized in Table 2. The role of MDR
transporters in rhodamine 123 transport, the reference ﬂuorescent
substrate for mammalian P-gp xenobiotic transport, has been dem-
onstrated in H. contortus eggs. Resistance to some anthelmintics,
e.g., benzimidazoles, was associated with a decrease in rhodamine
accumulation in eggs which indirectly reﬂected an increase in P-gp
activity in benzimidazole resistant worms (Beugnet et al., 1997).
By analogy to the regulation of mammalian P-gp activity by choles-
terol, changing cholesterol content in H. contortus affects the resis-
tance to benzimidazoles (Riou et al., 2003). A recent study
performed in H. contortus eggs conﬁrmed that rhodamine 123
was transported via mechanisms that can be inhibited by MDR
transporter inhibitors (Kerboeuf and Guegnard, 2011). In this mod-
el, no direct transport of anthelmintics was shown but MLs, which
inhibit P-gp-mediated efﬂux in mammals, activated the efﬂux of
rhodamine 123 in this nematode model. No direct relationship be-
tween the structure of the different MLs and their activity on rho-
damine 123 efﬂux was determined, as it was previously
demonstrated for mammalian P-gp (Lespine et al., 2007). In addi-
tion, levamisole appeared to interfere with rhodamine 123 trans-
port, while in a cell model overexpressing the mammalian
transporter, levamisole failed to inhibit P-gp (Dupuy et al., 2010).
This work suggests that mechanism of transport mediated through
MDR transporters may differ in nematodes compared with
mammals.
Further evidence for the interaction of P-gps, or other MDR
transporters, with ivermectin transport in parasites is indicated
by the capacity of typical P-gp inhibitors to increase the efﬁcacy
of ivermectin in susceptible worms or to reverse resistance in
resistant strains. Indeed, the in vitro susceptibility to ivermectin
of both sensitive and resistant isolates of Teladorsagia circumcincta
and H. contortuswas increased by valspodar, verapamil and by plu-
ronic acid (Bartley et al., 2009), a surfactant polyol which have
been shown to inhibit mammalian P-gp and to reverse multidrug
resistance in mammalian cells (Batrakova et al., 2003). Similarly,
studies performed on C. elegans have demonstrated that exposure
Table 2





References Other evidence References
C. elegans Ivermectin Expression level James and Davey (2009)
H. contortus Ivermectin Expression level Xu et al. (1998) MDR reversing agent Xu et al. (1998)
Prichard and Roulet (2007) Molento and
Prichard (1999)
Allelic changes Blackhall et al. (1998) Bartley et al. (2009)
Le Jambre et al., 1999
Sangster et al. (1999)
Moxidectin Expression level Prichard and Roulet (2007) MDR reversing agent Molento and
Prichard (1999)
Cambendazole Allelic changes Blackhall et al. (2008) MDR reversing agent Beugnet et al. (1997)
Thiabendazole
(Benzimidazoles)




T. circumcincta Ivermectin Polymorphism and
expression level
Dicker et al. (2011b) MDR reversing agent Bartley et al. (2009)
O. volvulus Ivermectin SNPs Ardelli and Prichard (2004,
2007)
Bourguinat et al. (2008)
Polymorphism Eng and Prichard (2005)
Eng et al. (2006)
Ardelli and Prichard (2004,
2007)
Ardelli et al. (2005, 2006a,b)
D. immitis Ivermectin SNPs Bourguinat et al. (2011a,b)
F. hepatica Triclabendazole MDR reversing agent Mottier et al. (2006)
Triclabendazole
sulfoxide
S. mansoni Praziquantel Expression level Messerli et al. (2009)
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mectin in an ivermectin resistant strain (James and Davey, 2009).
More recently, using a model of heterologous expression of H.
contortus P-gp A (HcP-gpA) in mammalian cells, preliminary data
on the direct interaction of the nematode transporter with xenobi-
otics were determined. This transporter was able to efﬂux rhoda-
mine 123 and this efﬂux was inhibited by verapamil, ivermectin
and moxidectin (Godoy and Prichard, personal communication)
with similar relative potencies as for mammalian P-gp inhibition.
Based on the likelihood that MLs also interact with nematode
transporters, this could be even more complex because of the mul-
tiplicity of transporters which are expressed in nematodes. In addi-
tion, the transporters differ between mammals and parasites and
further investigations need to be performed in order to describe
the precise interaction of different P-gps, MRPs and half-transport-
ers in parasites with MLs and typical MDR substrates/inhibitors.
In addition, there is some evidence that ivermectin could be in-
volved in the regulation of MDR transporters in nematodes. In C.
elegans an overexpression of several ABC transporters under iver-
mectin pressure has been reported which was suggested to be
associated with the ivermectin resistant phenotype of the worms
(Ardelli and Prichard, 2008). When the ivermectin resistant worms
were cultivated without ivermectin and then returned to ivermec-
tin, a different panel of regulation occurs for MDR transporters.
This suggests that some MDR transporters are involved in acquisi-
tion of resistance and others in the maintenance of resistance.
Interestingly, selection for ivermectin resistance in this model also
decreased sensitivity to levamisole but not to albendazole. Simi-
larly, in two strains of H. contortus experimentally selected with
ivermectin or moxidectin, expression of several P-gp genes was
modulated (Prichard and Roulet, 2007). The impact of these mod-
ulations on drug transport activity in nematodes and the mecha-
nisms responsible of these regulations remain to be deciphered.
The study of ABC transporters in nematodes is in its infancy and
it is helpful to consider their role in higher eukaryotes in order toappreciate their importance for affecting anthelmintic efﬁcacy in
nematodes. The role of these transporters in nematodes for the
transport of anthelmintics needs to be further researched.
2.4. Genetic evidence for contribution of MDR transporters to ML
resistance in nematodes
There is strong evidence that resistances to MLs involves P-gps
and other ABC transporters (Table 2). Given that MDR transporters
efﬂux a large variety of substrates out of the host organism, we can
assume that they also reduce the access of some anthelmintic
drugs to the worm tissues, limiting thus the anthelmintic efﬁcacy.
Furthermore, increases in the level of expression of some trans-
porters in anthelmintic resistant nematodes would reduce expo-
sure of sensitive receptors in resistant worms.
2.4.1. Caenorhabditis elegans
The expression of P-gps and MRPs was increased in ivermectin-
resistant strains of C. elegans which were generated through step-
wise exposure to increasing concentration, commencing with a
non-toxic ivermectin concentration of 1 ng/ml. The resistance
was stable for several weeks in the absence of ivermectin pressure
and the P-gp-1 gene appeared to be involved in acquiring low level
resistance, while themrp-1 gene may becomemore involved as the
level of resistance increases. In addition, the ivermectin-resistant
strains displayed a multidrug resistant phenotype with cross-resis-
tance to moxidectin, levamisole and pyrantel, but not to albenda-
zole. This provides evidence that ABC transporters have a role in
ivermectin resistance (James and Davey, 2009). However, no effect
on the ivermectin sensitivity was shown in C. elegans P-gp-1 and P-
gp-2 knock-out C. elegans (Broeks et al., 1995).
Using real-time reverse transcription PCR, the transcription of
eight MRPs was examined in wild-type and an ivermectin-recep-
tor-knock-out strain of C. elegans after drug exposure (Ardelli and
Prichard, 2008). Phenotype was then established in these strains
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in protecting C. elegans from drugs, the phenotype was examined
in C. elegans mrp-3, -4, -6 and -8 knock-out strains. Transcription
of all MRP genes increased after wild-type C. elegans were exposed
to ivermectin or moxidectin but was highest (up to 6-fold) for
MRP-3 after exposure to both MLs. The ivermectin-receptor-
knock-out strain differed from the wild-type in that the initial
stimulation of motility by 2.5 nM ivermectin changed to a rapid
reduction in motility followed by recovery. The response to moxi-
dectin was similar between the ivermectin-receptor-knock-out
and wild-type strains after exposure to moxidectin but differed
from that observed after exposure to ivermectin. The mrp-3, -4
and -8 deletion strains were more sensitive to ivermectin, whereas
the mrp-6 and -8 deletion strains were more sensitive to moxidec-
tin. This study provides evidence for the involvement of MRPs in
reducing the toxicity of ivermectin and moxidectin. However, it
is likely that a combination of several ABC transporters is required
for resistance to ivermectin.
2.4.2. Haemonchus contortus
In 1998, it was demonstrated that ivermectin-selected H. con-
tortus worms showed a higher expression level of P-gp-A com-
pared with a parental unselected strain (Xu et al., 1998). At the
same time, allelic differences, in H. contortus P-gps were found be-
tween ivermectin-resistant and -sensitive strains (Blackhall et al.,
1998; Le Jambre et al., 1999; Sangster et al., 1999). Furthermore,
the use of the MDR-reversing agents, verapamil and CL347099, in-
creased the efﬁcacy of ivermectin and moxidectin against resistant
H. contortus strains in jirds (Xu et al., 1998; Molento and Prichard,
1999). Since then, several other P-gp genes were reported in H.
contortus and ivermectin and moxidectin treatments select for a
constitutive or inducible overexpression of ﬁve P-gps in adult H.
contortus worms (P-gp-A, -B, -C, -D and -E) (Prichard and Roulet,
2007). The constitutive overexpression could be a result of muta-
tions in the regulatory sequences of the P-gp genes; such muta-
tions may be located in the promoter region or in introns.
However, the mechanism behind the inducible overexpression is
less clear. A recent study explored nine P-gp homolog sequences
in H. contortus to investigate potential changes in the expression
levels of P-gp transcripts associated with ivermectin resistance
(Williamson and Wolstenholme, 2011). No signiﬁcant changes in
P-gp mRNA expression levels were found in a rapidly selected iver-
mectin-resistant parasite isolate compared to its drug-sensitive
parent isolate. However, some of the primers used for the qRT-
PCR may not have been speciﬁc for individual P-gp genes, amplify-
ing more than a single gene.
2.4.3. Teladorsagia circumcincta
Constitutive overexpression of 10 of 11 T. circumcincta P-gps
was determined in a triple-resistant isolate compared with a sus-
ceptible isolate of this ovine nematode parasite, with the most
notable difference being in Tci-P-gp-9 which was overexpressed
in all life-cycle stages examined and at levels up to 55X higher than
in the susceptible isolate. Polymorphic differences were also iden-
tiﬁed in the partial Tci-P-gp-9 nucleotide sequence of a triple-resis-
tant isolate of this nematode compared with the susceptible isolate
(Dicker et al., 2011b). The genetic changes underpinning these
gene expression changes remain to be elucidated and need to be
investigated in other isolates. When the resistant isolate was ex-
posed to ivermectin in vitro, the transcriptomic response revealed
statistically signiﬁcant differences in the mean expression levels
of four KEGG orthologous groups, namely ‘translation’, ‘amino acid
metabolism’, ‘carbohydrate metabolism’ and ‘xenobiotic degrada-
tion and metabolism’. However, candidate resistance genes such
as P-glycoproteins and cytochrome P450s were poorly represented
in both datasets (Dicker et al., 2011a).2.4.4. Onchocerca volvulus
Recently, ivermectin resistance has been reported in O. volvulus
(Osei-Atweneboana et al., 2007, 2011). Genetic variation of O. vol-
vulus ABC transporter homologues, from several populations in
Africa, was examined to determine if an association exists between
alleles of these genes and ivermectin treatment. A reduction in ge-
netic polymorphism was shown in two ABC transporter genes, des-
ignated OvMDR-1 and OvABC-1, in O. volvulus from ivermectin
treated patients. A number of SNPs were identiﬁed in the alleles
of these genes. However, the majority of SNP polymorphisms iden-
tiﬁed resulted in synonymous or silent mutations, although several
of the SNPs were located in coding regions (Ardelli and Prichard,
2004). For another ABC transporter gene, designated OvABC-3, a
more extensive study was performed on O. volvulus from patients
in several countries in both East andWest Africa (Ardelli and Prich-
ard, 2007). Allelic variation of this gene in non-treated populations
showed this locus to be highly polymorphic. However, variability
in the OvABC-3 was reduced in ivermectin treated populations. In
1997, the Ghana National Control Programme and the Onchocerci-
asis Control Program (OCP) identiﬁed 31 individuals in the Lower
Black Volta and Pru River Basins in Ghana with a persistent micro-
ﬁladermia despite repeated ivermectin treatments (Awadzi et al.,
2004a). Parasite material was collected from these patients and
genotyped for OvABC-3. Five polymorphs of OvABC-3 were de-
tected and one polymorph, polymorph C, was in higher frequency
in sub-optimal responders. However, it should be noted that only a
small number of worms were collected.
In another investigation, a signiﬁcant difference in the genetic
polymorphism of O. volvulus P-glycoprotein (OvP-GP-1) (Huang
and Prichard, 1999) between worms collected from untreated peo-
ple and worms from people and communities that had been
repeatedly treated with ivermectin in Ghana was ﬁrst reported
by (Eng and Prichard, 2005; Eng et al., 2006). Furthermore, while
the OvP-GP-1 was in Hardy–Weinberg equilibrium in the worms
from untreated people, it was not in Hardy–Weinberg equilibrium
in the samples from treated people, indicating that genetic selec-
tion on this gene was occurring. The genetic diversity of 28 loci
spanning the entire OvP-GP-1 gene was examined in four O. volvu-
lus populations from the Volta Region of Ghana (Ardelli et al., 2005;
Ardelli et al., 2006a). These populations ranged from no ivermectin
treatment to 4–10 treatments. Samples collected from the same
villages in 2002 showed a dramatic loss of polymorphism, even
in non-treated samples. Taken together, these results suggest that
the use of ivermectin in Ghana for onchocerciasis control is exert-
ing selection pressure on this P-gp gene and, as a result, is reducing
genetic diversity. Several of the loci examined showed differences
in the frequencies of different sequences.
A total of 12 genetic markers, spanning the entire O. volvulus
half ABC-transporter (OvPLP-1), were examined (Ardelli et al.,
2006b) in the same ﬁeld population as in previous studies (Ardelli
et al., 2005, 2006a). Although many of the regions remained poly-
morphic after treatment, there was a loss of several polymorphs in
many regions of the gene. The study also indicated a region of the
OvPLP-1 gene, the loop region between TM4 and TM5, that may be
a good marker for monitoring ivermectin selection in O. volvulus,
and speciﬁc SNPs, including a coding SNP, have been identiﬁed in
ivermectin-selected populations from Cameroon, which may be
useful as markers for possible ivermectin resistance development
(Bourguinat et al., 2008). Linkage disequilibrium (LD) is a pattern
of association between two SNPs or two loci and is affected by
many factors, such as genetic recombination, population subdivi-
sion, selection, inbreeding and ﬂuxes in population size. Population
bottlenecks increase LD. Strong selection for a particular allele lim-
its genetic diversity around a locus, resulting in a short-term in-
crease in LD around the selected gene. Ardelli et al. (2006a,b)
used LD to determine gene(s) or ‘hotspots’ that might be involved
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vulus ABC transporters (OvP-GP-1 and OvPLP-1). In both of these
studies, the number of regions in LD decreased in these ABC trans-
port genes with repeated ivermectin treatment and the non-trea-
ted populations always showed more LD than treated
populations. These data make a strong case that ivermectin is
affecting the genetic diversity of O. volvulus and selecting on ABC
transport genes. Most of the signiﬁcant reduction in genetic diver-
sity was localized to the region between the fourth and ﬁfth trans-
membrane domains of the O. volvulus half-transporter and there
was minimal LD in this area. This suggests that the region may
be useful as a tool to monitor the effect of ivermectin on O. volvulus
populations. To try to determine the effects of ivermectin on O. vol-
vulus populations, an analysis of genomic diversity within treated
and non-treated populations was undertaken, using estimates of
genetic diversity in the genes OvP-GP-1 and OvPLP-1 (Ardelli
et al., 2005, 2006a,b). The most dramatic difference was observed
in the OvP-GP-1 gene, where there was a signiﬁcant loss of gene
diversity with treatment and with time and the most signiﬁcant ef-
fects were observed after 4–6 rounds of ivermectin treatment. Fol-
low up work determined SNPs in the OvPLP-1 genomic sequence,
including an amino acid coding change, which may be useful as ge-
netic markers for ivermectin selection in O. volvulus (Bourguinat
et al., 2008).
2.4.5. Diroﬁlaria immitis
A genetic association between a P-gp gene and loss of efﬁcacy of
MLs against D. immitis, the causative agent of Heartworm disease in
dogs and cats, has been reported. Bourguinat et al. (2011b) found a
high correlation (r2 = 0.978) between a GG-GG genotype in the D.
immitis P-glycoprotein gene (Accession No.: HM596853) and
in vitro response of microﬁlariae to ivermectin. In another study,
the response to treatment in a heartworm-positive dog and the fre-
quency of the same P-gp genotype were determined (Bourguinat
et al., 2011a). Microﬁlariae were isolated from a Katrina rescue
dog that remained microﬁlariaemic despite successful adulticidal
treatments and repeated treatments with high doses of ivermectin
and milbemycin oxime. The microﬁlariae were genotyped at the
same two P-gp single nucleotide polymorphic sites which had been
found to correlate with reduced in vitro sensitivity to ivermectin in
the Bourguinat et al. report (Bourguinat et al., 2011b). The genetic
polymorphism (GG–GG), previously found to be associated with
insensitivity to MLs in vitro, was present at a frequency of 45.3%
in microﬁlariae that survived repeated in vivo treatments with high
doses of ivermectin andmilbemycin oxime. These data show in vivo
and in vitro phenotypic and genotypic evidence of ML resistance in
D. immitis microﬁlariae and the possible use of this P-gp genotype
as a marker for ML resistance in D. immitis.
2.5. MDR transporters in resistance to anthelmintics other than MLs in
helminths
Beside selection on b-tubulin (see Section 2.1), a secondary
mechanism of BZ resistance, possibly involving ABC transporters,
has been reported in the ruminant GIN, H. contortus. Verapamil,
an established ABC transport inhibitor, was able to partially re-
verse resistance to BZs in H. contortus (Beugnet et al., 1997). The
selection of a speciﬁc P-gp-A allele was described in cambendazole-
and thiabendazole-resistant H. contortus strains compared with a
parental susceptible strain (Blackhall et al., 2008). Assuming that
this P-gp locus is not genetically linked to a b-tubulin locus, these
data provide evidence for a possible involvement of a P-gp, in addi-
tion to target modiﬁcation, in resistance to BZs. In addition, signif-
icantly lower concentrations of triclabendazole and
triclabendazole sulfoxide were recovered within triclabendazole-
resistant F. hepatica and the efﬂux of triclabendazole was de-creased in resistant ﬂukes in the presence of ivermectin used as
inhibitor of drug transporters. This supports the idea that MDR
transporters play a role in resistance to triclabendazole (and tricla-
bendazole sulfoxide) in ﬂukes (Mottier et al., 2006). Given that
verapamil and ivermectin are non-speciﬁc for P-gp and that BZs
interact with other ABC transporters such as BCRP (Merino et al.,
2005), we cannot exclude the possibility that some transporters
other than P-gps, may also play a role in BZ resistance.
There is little speciﬁc evidence of ABC transporter involvement
in closantel resistance but a lower concentration of closantel was
found in closantel-resistant H. contortus than in closantel suscepti-
ble nematodes, suggesting that resistance to this anthelmintic
could involve enhanced drug efﬂux (Rothwell and Sangster,
1997). Because closantel interferes with mammilian P-gp in vitro
(Dupuy et al., 2010), it may also interact with P-gp or may induce
expresssion of transporters in helminths. Closantel is sometimes
combined with ivermectin in order to enlarge anthelmintic spec-
trum against gastrointestinal nematodes and liver ﬂuke (Borgste-
ede et al., 2008). The co-administration of these two P-gp
substrates could accelerate the development of cross-resistance
by genetic selection and induction of P-gps in nematodes or in liver
ﬂukes. To date, there is no report on the possible inﬂuence of
anthelmintic combinations on the development of resistance in
the target parasites, but one can expect that resistance occurring
through P-gp selection could be accelerated when combination of
two P-gp substrates, such as ivermectin and triclabendazole, or
closantel, are intensively used.
2.6. Possible mechanisms of MDR transporter regulation in nematodes
In parasitic organisms, MDR transporter homolog genes are se-
lected under ML pressure (Ardelli and Prichard, 2007) and several
were shown to be overexpressed in ivermectin-resistant worms
such asH. contortus (Xu et al., 1998) and C. elegans (James andDavey,
2009). It is noteworthy to mention that such induction has been re-
ported under anthelmintic pressure in organisms other than nema-
todes, after exposure to the ML emamectin in the marine parasitic
sea lice Lepeophtheirus salmonis (Tribble et al., 2007). Similarly, fol-
lowing exposure to sub-lethal concentrations of praziquantel, levels
of RNA for SMDR2, a Pgp homologue from S. mansoni, increase tran-
siently in adult male worms (Messerli et al., 2009).
The genomic changes in ABC transporter genes that have been
observed in response to ivermectin or exposure to other MLs,
and which are associated with a ML resistance phenotype in nem-
atodes could be a result of several regulatory events that still need
to be clearly identiﬁed. In C. elegans, the homolog NHR-8 is in-
volved in xenobiotic resistance to colchicine and chloroquine
(Lindblom et al., 2001; Lindblom and Dodd, 2006). In addition,
the overexpression of a P-gp homolog in the protozoan parasite
Plasmodium falciparum was recently shown to occur through a nu-
clear-mediated response which was similar to the mammalian
drug-inducible system (Johnson et al., 2008). Altogether, these data
strongly suggest that exposure to MLs could modulate MDR trans-
porters in both mammals and parasites and lead us to consider that
similarities in the mechanisms of MDR transporter regulation
could exist between mammals and parasites.
One of the strategies to decipher the involvement of the ABC
transporters or possible regulators in resistance to MLs and to re-
verse resistance could be to switch off the over-expressed or target
genes in the resistant C. elegans strains by deletion or by RNAi.
However, the task is complex because several ABC transporters
are likely to be involved and we may need to target all the trans-
porters involved in the resistance. In the case where nuclear recep-
tors are involved in the regulation of MDR transporters, targeting
themmay be a powerful tool and may switch-off several transport-
ers at the same time.
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MLs or by indirect processes remains to de determine. Indeed, P-gp
expression can be modulated by xenobiotics but also by oxidative
stress. Under conditions of chronic oxidative stress induced by glu-
tathione depletion, P-gp expression was induced in rat brain
microvessels (Hong et al., 2006). Thus, induction of the expression
of the MDR genes may happen secondarily to deleterious oxidative
processes that occur in nematodes exposed to anthelmintic drugs.
3. Pharmacolgical reversion of MDR transporter-mediated
resistance
Because an effective concentration of anthelmintic during a
suitable length of time is needed, in the target organisms, to
achieve therapeutic activity, the inhibition or modulation of P-gp
activity represents a possible strategy to increase drug concentra-
tion in the target and subsequently the efﬁcacy of anthelmintics
and particularly the MLs (Lespine et al., 2008). This strategy is
the same principle as that previously developed in humans to tar-
get multidrug resistance in cancer (Nobili et al., 2006). Substances
known to inhibit mammalian P-gp are able, when co-administered
with MLs, to increase the efﬁcacy of the drug against susceptible
and also resistant worms. This is an encouraging strategy to opti-
mize anthelmintic efﬁcacy against resistant strains and some
examples of possibilities for pharmacologically reversing, or over-
coming anthelmintic resistance due to MDR transporters are given
below and summarized in Fig. 2.
3.1. Inhibition of MDR transporter-mediated efﬂux
By using MDR-reversing agents, the pumping action of the
transporters would be minimized, and the ML concentration would
increase in the plasma and tissues of the host thus offering theFig. 2. Putative targets for reversing multidrug transporter-mediated resistance. Differen
the case of MDR transporter-mediated resistance and to overcome this resistance. (i) Inhi
of MDR transporter gene expression at transcriptional level through an inhibition of trans
of the MDR mRNA stability in the cell (iib). (iii) Modulation of lipid composition of th
depletion to decrease the basal activity of MDR transporters. (iv) Another side mechani
stress with an increase of reactive oxygen species (ROS) production and cell damage resexpectation of increased anthelmintic efﬁcacy (Lespine et al.,
2008). Most of the data supporting this assumption have been gen-
erated in models of mammalian transporters. However, in the case
of ML resistance, the MDR transporters of the target nematode
should be considered. In an idealistic view, the inhibitor should
target speciﬁcally the parasite, to allow the drug to enter preferen-
tially into the target, without modifying the host transporter. How-
ever, because little is known about nematode transporters,
approaches have, so far, consisted of selecting inhibitors on the ba-
sis of their potency to inhibit mammalian MDR transporters.
Drugs which are inhibitors of MDR transporters have been
tested in several animal models infected with gastrointestinal
nematodes. Verapamil, imidazole derivatives, quercetin, lopera-
mide and other anthelmintics such as triclabendazole, are able to
interact with mammalian P-gp function in vitro, and they signiﬁ-
cantly increased drug bioavailability when they were co-adminis-
trated in vivo with ivermectin and sometimes with moxidectin
(see Section 3.1.6). Recent studies validate the effectiveness of
some of these inhibitors in pharmacologically reversing ML resis-
tance in nematodes in vitro. Indeed, the combination of P-gp inhib-
itors such as valspodar, verapamil, ketoconazole or quercetin with
ivermectin enhanced ivermectin efﬁcacy in sensitive isolates, and
also restored ivermectin susceptibility in resistant H. contortus
and T. circumcincta nematodes (Bartley et al., 2009).
Several studies have shown the effectiveness of co-administra-
tion of MLs and MDR inhibitors on drug efﬁcacy in animals infected
with ML-susceptible or resistant isolates (Table 1). Indeed, im-
proved anthelmintic efﬁcacy of MLs on ivermectin-resistant nem-
atode isolates was observed in cattle and sheep when it was
combined with loperamide, possibly due to enhanced plasma
availability and prolonged elimination half-life of ivermectin, (Lifs-
chitz et al., 2010a,b) and possibly direct effects on the nematode
transporters. Similarly, co-administration of triclabendazole witht strategies could be considered to increase drug concentration in the target cell in
bition of MDR transporter-mediated efﬂux by using MDR inhibitors. (ii) Modulation
criptional regulator activity (iia); or at post-transcriptional level through a decrease
e cell membrane harbouring the MDR transporters with surfactants or cholesterol
sm associated with the presence of MDR substrates is the modulation of oxidative
ulting in apoptosis induction.
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sheep naturally infected with gastrointestinal nematodes (Marti-
nez-Valladares et al., 2010). In addition, recent studies have shown
that pluronic enhanced the anthelmintic activity of ivermectin
against ivermectin-resistant H. contortus isolates (Bartley, personal
communication). These data are in accordance with an inhibition
of host MDR transporters and other studies are needed to demon-
strate whether MDR inhibitors have direct effects on MDR trans-
porters in nematodes.
This offers new possibilities for these products, which are al-
ready registered and marketed for veterinary anthelmintic use, to
be used in combination not only to broaden the spectrum of activ-
ity but also as potent P-gp inhibitors. It could also be envisaged
that the co-administration of these inhibitors might improve the
efﬁcacy of the MLs against some of the current ‘dose limiting’ par-
asite species, such as Cooperia spp., Nematodirus spp. and Cyathost-
omes. However, because these compounds inhibit host MDR
transporters, the possible neurotoxicity of avermectins dictates
caution in their use for this purpose in mammals.
Apart from the molecules described above, a large number and
variety of structurally unrelated compounds have been described
which inhibit or interfere with MDR mediated transport (Nobili
et al., 2006). Because many of these may enhance the activity of
anthelmintics which are substrates of MDR transporters, such as
ivermectin, they provide hope for ﬁnding novel inhibitors of nem-
atode transporters (Table 1).
Nevertheless, there are some limitations to using such an ap-
proach. On the one hand, these drugs share MDR transporter gene
selection as common cross-resistance mechanisms and their
in vivo combination could accelerate the selection for anthelmintic
resistant strains. Secondly, the safety of the MDR inhibitors needs
to be considered for the success of such a strategy, encouraging
the search for safe and speciﬁc compounds. In this context, poly-
therapy may be a challenge to safely optimize the efﬁcacy of drugs
that are substrates of P-gps or other transporters. The major miss-
ing points needed to achieve this objective for MLs are data con-
cerning the afﬁnity of these compounds for P-gp homologues
from parasites, and the ability of referenced MDR transport inhib-
itors to interact with ML efﬂux in parasites. In addition, the possi-
ble side-effects of the inhibitors and the relative short persistence
of these products compared with that of MLs need to be taken into
account. In fact, for the MLs, considerable data remain to be gener-
ated in order to better deﬁne the mechanisms that sustain ML-drug
and ML/food interactions. In general, clinical trials of MDR revers-
ing agents against multidrug resistant cancers have been unsuc-
cessful (Nobili et al., 2006; Szakacs et al., 2006). Blocking the
transporter may impair the homeostasis of important endogenous
substrates and that could induce toxicity and/or induce adverse
reactions. Therefore, the current dogma is that, for a reversing
agent to be successful, speciﬁcity is crucial in order to preserve
the activity of related transporters displaying overlapping
speciﬁcities.
3.2. Targeting regulation pathway of MDR transporter gene expression
Alternatively, instead of targeting the MDR transporters them-
selves, one could also target the mechanisms involved in the induc-
tion of the MDR transporters, for example homologues of nuclear
receptors, which are known to induce P-gp expression in mamma-
lian cells when activated by ligands (Staudinger et al., 2003). In-
deed, in C. elegans, several ‘‘xenosensors’’ called nuclear hormone
receptors (NHR) have been reported to be involved in colchicine
and chloroquine resistance; these chemicals being cytochromes
and P-gp substrates. This suggests that similar regulatory mecha-
nisms for detoxiﬁcation systems exist in nematodes, which could
also be exploited to improve drug availability in the parasite.Assuming that similar ‘‘xenosensor’’-dependant pathways are in-
volved in the regulation of MDR transporters in nematodes, antag-
onism of such nuclear receptor homologues could potentially
down-regulate the P-gp expression. In parasitic nematodes, things
are less clear. However, advances in H. contortus genomics will pro-
vide useful tools to increase the knowledge about mechanism of
resistance in parasitic nematodes.
3.3. Modulation of membrane lipid composition and stability
By analogy with the already described methods of chemosensi-
tization of cytotoxic drugs used against MDR tumour cells, it could
be proposed to improve the efﬁciency of MLs, when they are lim-
ited by MDR transporters, by using ‘‘non-speciﬁc’’ inhibitors acting
via a perturbation of the membrane phase, typically involving sur-
factants, or altering the lipid composition of the cell membrane
harbouring the MDR transporters. The potential of lipids or lipid
excipients to attenuate the drug efﬂux by P-gp has generated con-
siderable interest (Batrakova et al., 2001; Cornaire et al., 2004; See-
lig and Gerebtzoff, 2006). The activity of P-gp and other MDR
transporters are modulated by the lipid composition of the sur-
rounding membrane of the cells.
Membrane cholesterol has a positive inﬂuence on P-gp function,
and this may be a direct effect of the free cholesterol present in
membrane or an indirect effect mediated by the cholesterol-en-
riched microdomain (Orlowski et al., 2006). Cholesterol depletion
in cell membranes leads to inhibiton of basal P-gp ATPase activity.
In addition, cholesterol in membranes favours the transport of
BCRP substrates (Pal et al., 2007). Interestingly, regulation was
found in parasites and cholesterol depletion caused increased
resistance whereas cholesterol loading decreased resistance. It
has been postulated that these results are related to the modula-
tion of the activity of P-gp homologues in the nematodes (Riou
et al., 2003). In addition, lipid-based formulation strategies were
proposed for enhancing the intestinal transport and absorption of
P-gp substrate drugs (Constantinides and Wasan, 2007). However,
their mechanism of action is still a matter of debate as to whether
they act indirectly on P-gp function, viamembrane perturbation, or
stimulate the cellular uptake of hydrophobic drugs.
These data suggest that designed lipid formulations could also
be envisaged for increasing the ML concentration in both hosts
and parasites.
3.4. Modulation of oxidative stress and increase of apoptosis
There is increasing evidence that MDR substrates might also be
used to target the parasites in a different way. It has been shown
that the exposure of cells to P-gp substrates leads to an increase
in reactive oxygen species due to a higher ATP use and the need
for higher rates of ATP synthesis. This may ultimately result in cell
apoptosis (Karwatsky et al., 2003). If this mechanism also exists in
parasites, it may mean that anthelmintic resistant nematodes, with
higher activity of MDR transporters, could be made more sensitive
to apoptosis mechanisms than would be wild-type anthelmintic-
sensitive parasites; an interesting scenario for combating anthel-
mintic resistance. However, it would be important that the MDR
competitors used be parasite-speciﬁc, otherwise host cells might
also be affected.
3.5. Other genes possibly involved in resistance
An important point to consider is that ML resistance had been
proposed to be multigenic. In this regards, even though a reversing
agent may partially overcome the resistance, the fact that receptor-
related resistance mechanism could also be involve in ML resis-
tance, may reduce the impact of inhibiting MDR mechanisms.
A. Lespine et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 58–75 71A mutation on the gene encoding prohibitin 2 has been shown
to induce resistance to several toxins or drugs in C. elegans. Given
that some of the compounds tested are not substrates of mamma-
lian P-gp, it is unlikely that mechanisms of resistance described in
this work are related to MDR transporters. Nevertheless, we cannot
exclude the possibility that the compounds tested are substrates of
C elegans MDR or that prohibitin 2 controls the intracellular con-
centration of certain toxins by inhibiting drug efﬂux, degradation
or activates drug inﬂux (Zubovych et al., 2006). Further work needs
to be done to determine if the mutants are also resistant to
ivermectin.4. Conclusion
In the context of the spread and economic impact of anthelmin-
tic resistance in veterinary nematodes, it is urgent to understand
the mechanisms and genetics of anthelmintic resistance, to moni-
tor for anthelmintic resistance and to propose strategies to delay or
reverse resistance in the target parasites. The recent evidence of
the emergence of anthelmintic resistance in human nematode par-
asites compounded by the recent massive expansion of mass che-
motherapy control programs around the world, for parasites such
as O. volvulus,Wuchereria bancrofti, and soil transmitted helminths,
adds urgency to understand anthelmintic resistance and to develop
markers which can be used to monitor for resistance in these
programs.
In nematodes, the mechanisms of anthelmintic resistance
development remain unclear and this affects the prospects for
developing sensitive molecular markers and for pharmacologically
reversing resistance.
Given the strong interaction of MLs with mammalian P-gp, and
given the central role that ABC transporters play in ML resistance
in nematodes, developing strategies that target these transporters
or the actors that are involved in their regulation is important. This
is even more critical because a large number of drugs currently
developed, including anthelmintics, are potential MDR transporter
substrates and cross resistance involving these transporters can
impaired the therapeutic outcome of many control efforts.
The most probable strategy remains the inhibition of MDR
transporters responsible for efﬂux of active compounds out of
the target. This can be envisaged on the basis of the huge advances
in research on multidrug resistance reversion in cancer therapy. In-
deed, cancer cells become resistant to many compounds by
increasing the expression of MDR transporters and much work
provides encouraging data on the possibilities for pharmacologi-
cally reversing this resistance, although no ideal inhibitors have
been found so far.
Today, the ﬁrst challenge to improve anthelmintic therapy and
reversing resistance, is to overcome the lack of knowledge con-
cerning the role of nematode ABC transporters in the drug efﬂux
and to determine their speciﬁcity when compared to mammalian
MDR transporters. If beneﬁts are to be gained in nematode control
from efﬂux pump inhibition; several criteria need to be satisﬁed.
The molecule(s) must be speciﬁc for the transporters of the target
organism. The duration of blockage needs to be long enough to al-
low for persistent inhibition. It should be administered at a dose
compatible with standard clinical doses in order to reduce toxicity.
So far, tremendous numbers of MDR inhibitors have been screened
for cancer therapy; however, the ideal reversal agent has not been
found for polychemio-resistance, or for anthelmintic resistance.
Finally, by using global genetic, protein or metabolic ap-
proaches, it may be possible in the near future to identify new
mechanisms associated with ML resistance that may help to dis-
cover new possible targets and to overcome to ML resistance.
Understanding the mechanisms involved in resistance to existinganthelmintics can also be important in the development of new
anthelmintics in order to avoid possible cross resistance and the
rapid selection of resistance to the new entities.
Thus, increasing knowledge of anthelmintic receptors, changes
in those receptors and their genes which cause resistance, the role
of ABC transporters in resistance and of nuclear receptors in regu-
lating protein expression in parasites should be prioritized for fu-
ture research.
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